

Article

Effects of Dupilumab on Itch-Related Events in Atopic Dermatitis: Implications for Assessing Treatment Efficacy in Clinical Practice


Ryoma Kishi ^{1,2}, Sumika Toyama ¹, Mitsutoshi Tominaga ^{1,3}, Yayoi Kamata ^{1,3}, Eriko Komiya ¹, Takahide Kaneko ², Yasushi Suga ^{2,3} and Kenji Takamori ^{1,2,3,*}

¹ Juntendo Itch Research Center (JIRC), Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu, Chiba 279-0021, Japan

² Department of Dermatology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, Chiba 279-0021, Japan

³ Anti-Aging Skin Research Laboratory, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu, Chiba 279-0021, Japan

* Correspondence: ktakamor@juntendo.ac.jp; Tel.: +81-47-353-3171



Supplementary Figure S1. Correlation analysis of VAS scores with IgE, eosinophils, IL-4, IL-13, IL-31 and IENFs. (a–f) Correlation analysis of VAS scores with (a) serum IgE levels, (b) Number of eo-sinophils in peripheral blood, (c) serum levels of IL-4, (d) serum levels of IL-13, (e) se-rum levels of IL-31, and (f) number of IENFs. Data are shown as the mean $\pm$ standard error of the mean (n=12 per group). Coefficients (r) were assessed by Spearman's rank correlation test. *P<0.05. VAS, visual analogue scale; EASI, eczema area and severity index; IgE, immunoglobulin E; IL, interleukin; IENFs, intraepidermal nerve fibers; TARC, thymus and activation-regulated chemokine; ns, not significant.